


HEALTHCARE

## **The CNS Market Outlook to 2011**

By Revati Nehru

 [Table of Contents](#)

## **Revati Nehru**

Revati Nehru is a healthcare analyst, with 3 years' experience in healthcare marketing and market analysis in cancer and cardiovascular. During this time she has worked for multinational pharmaceutical companies and independent research houses. She is currently employed as a healthcare market analyst.

Copyright © 2006 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The CNS Market Outlook to 2011

<b>Executive Summary</b>	<b>10</b>
Patient potential	10
Global market analysis	11
Analysis of potential future CNS blockbusters	12
Leading players in the CNS market	13
<b>Chapter 1           Patient potential</b>	<b>16</b>
Summary	16
Introduction	17
<b>Alzheimer's disease</b>	<b>18</b>
Background	18
Diagnosis and treatment	20
Prevalence	22
Forecast prevalence of Alzheimer's disease	23
<b>Depression</b>	<b>25</b>
Background	25
Diagnosis and treatment	27
Prevalence	29
Forecast prevalence of depression/anxiety	29
<b>Epilepsy</b>	<b>31</b>
Background	31
Diagnosis and treatment	31
Prevalence	32
Forecast prevalence of epilepsy	33
<b>Migraine</b>	<b>35</b>
Background	35
Diagnosis and treatment	36
Prevalence	37
Forecast prevalence of migraine	38
<b>Parkinson's disease</b>	<b>39</b>
Background	39
Diagnosis and treatment	40
Prevalence	41

Forecast prevalence of Parkinson's disease	42
<b>Schizophrenia</b>	<b>43</b>
Background	43
Diagnosis and treatment	44
Prevalence	45
Forecast prevalence of schizophrenia	46

## **Chapter 2                      Global market analysis                      50**

<b>Summary</b>	<b>50</b>
<b>Introduction</b>	<b>51</b>
<b>Alzheimer's disease</b>	<b>52</b>
Introduction	52
Analysis of the leading Alzheimer's disease treatments	54
Market analysis by drug class	56
Cholinesterase inhibitors	56
NMDA antagonists	63
<b>Depression</b>	<b>65</b>
Introduction	65
Analysis of the leading anti-depressant treatments	67
Market analysis by drug class	69
Selective serotonin reuptake inhibitors	69
Serotonin norepinephrine reuptake inhibitors	76
Others	80
<b>Epilepsy</b>	<b>83</b>
Introduction	83
Analysis of the leading epilepsy treatments	84
Market analysis by drug class	87
Traditional anti-convulsants	87
Second generation anti-convulsants	93
<b>Parkinson's disease</b>	<b>99</b>
Introduction	99
Analysis of the leading Parkinson's disease treatments	100
Market analysis	102
COMT inhibitors	102
Dopaminergics	104
Dopamine agonists	106
<b>Migraine</b>	<b>112</b>
Introduction	112
Analysis of the leading migraine treatments	113
Market analysis by drug class	115
Triptans	115
<b>Schizophrenia</b>	<b>121</b>
Introduction	121
Analysis of the leading anti-psychotic treatments	123
Market analysis by drug class	126



Marketed products	180
R&D compounds	182
CNS portfolio sales forecasts	184
<b>Lilly</b>	<b>185</b>
Marketed products	185
R&D compounds	186
CNS portfolio sales forecasts	187
<b>Sanofi-Aventis</b>	<b>188</b>
Marketed products	188
R&D compounds	189
CNS portfolio sales forecasts	190
<b>AstraZeneca</b>	<b>192</b>
Marketed products	192
R&D compounds	193
CNS portfolio sales forecasts	194
<b>Wyeth</b>	<b>195</b>
Marketed products	195
R&D compounds	196
CNS portfolio sales forecasts	198
<b>Novartis</b>	<b>199</b>
Marketed products	199
R&D compounds	200
CNS portfolio sales forecasts	201
<b>Forest Labs</b>	<b>202</b>
Marketed products	202
R&D compounds	203
CNS portfolio sales forecasts	205
<b>Chapter 5</b>	<b>Appendix</b>
	<b>208</b>
<b>Glossary</b>	<b>208</b>
<b>Index</b>	<b>212</b>

# List of Figures

Figure 2.1:	Competitive dynamics of drug classes in the Alzheimer's disease market, 2005	53
Figure 2.2:	Competitive dynamics of leading brands in the Alzheimer's disease market, 2005	55
Figure 2.3:	Competitive dynamics of drug classes in the depression market, 2005	66
Figure 2.4:	Competitive dynamics of leading brands in the depression market, 2005	68
Figure 2.5:	Competitive dynamics of drug classes in the epilepsy market, 2005	84
Figure 2.6:	Competitive dynamics of leading brands in the epilepsy market, 2004–05	86
Figure 2.7:	Competitive dynamics of leading brands in the Parkinson's disease market, 2005	101
Figure 2.8:	Competitive dynamics of leading brands in the migraine market, 2005	114
Figure 2.9:	Competitive dynamics of drug classes in the schizophrenia market, 2004–05	122
Figure 2.10:	Competitive dynamics of leading brands in the schizophrenia market, 2004–05	125
Figure 3.11:	Leading drugs in development, 2005	143
Figure 4.12:	Key players in the global CNS market, 2001 and 2005	172

# List of Tables

Table 1.1:	Prevalence of Alzheimer's disease in the seven major markets, 2005	22
Table 1.2:	Forecast prevalence of Alzheimer's disease in the seven major markets, 2006-11	24
Table 1.3:	Prevalence of MDD/anxiety in the seven major markets, 2005	29
Table 1.4:	Forecast prevalence of depression/anxiety in the seven major markets, 2006-11	30
Table 1.5:	Prevalence of epilepsy in the seven major markets, 2005	33
Table 1.6:	Forecast prevalence of epilepsy in the seven major markets, 2006-11	34
Table 1.7:	Prevalence of migraine in the seven major markets, 2005	37
Table 1.8:	Forecast prevalence of migraine in the 7 major markets, 2006-11	38
Table 1.9:	Prevalence of Parkinson's disease in the seven major markets, 2005	41
Table 1.10:	Forecast prevalence of Parkinson's disease in the seven major markets, 2006-11	42
Table 1.11:	Prevalence of schizophrenia in the seven major markets, 2005	45
Table 1.12:	Forecast prevalence of schizophrenia in the seven major markets, 2006-11	47
Table 2.13:	Breakdown of the global Alzheimer's disease market by drug class, 2001-05	52
Table 2.14:	Breakdown of the global Alzheimer's disease market by leading brands, 2004-05	54
Table 2.15:	Breakdown of the global depression market by drug class, 2001-05	65
Table 2.16:	Breakdown of the global depression market by leading brands, 2004-05	67
Table 2.17:	Breakdown of the global epilepsy market by drug class, 2001-05	83
Table 2.18:	Breakdown of the global epilepsy market by leading brands, 2004-05	85
Table 2.19:	The global Parkinson's disease market, 2004-05	99
Table 2.20:	Breakdown of the global Parkinson's disease market by leading brands, 2004-05	100
Table 2.21:	Breakdown of the global migraine market by drug class, 2001-05	112
Table 2.22:	Breakdown of the global migraine market by leading brands, 2004-05	113
Table 2.23:	Breakdown of the global anti-psychotics market by drug class, 2001-05	121
Table 2.24:	Breakdown of the global anti-psychotics market by leading brands, 2004–05	123
Table 2.25:	Forecast global sales for major CNS indications, 2005-11	139
Table 4.26:	Key players in the global CNS market, 2005	170

Table 4.27:	J&J's marketed CNS portfolio, 2005	173
Table 4.28:	J&J's CNS R&D pipeline, 2006	175
Table 4.29:	Forecast sales for J&J's CNS portfolio, 2005–11	175
Table 4.30:	Pfizer's marketed CNS portfolio, 2005	177
Table 4.31:	Pfizer's CNS R&D pipeline, 2006	178
Table 4.32:	Forecast sales for Pfizer's CNS portfolio, 2005–11	179
Table 4.33:	GSK's marketed CNS portfolio, 2005	181
Table 4.34:	GSK's CNS R&D pipeline, 2006	182
Table 4.35:	Forecast sales for GSK's CNS portfolio, 2005–11	184
Table 4.36:	Lilly's marketed CNS portfolio, 2005	185
Table 4.37:	Lilly's CNS R&D pipeline, 2006	186
Table 4.38:	Forecast sales for Lilly's CNS portfolio, 2005–11	187
Table 4.39:	Sanofi-Aventis' marketed CNS portfolio, 2005	188
Table 4.40:	Sanofi-Aventis' CNS R&D pipeline, 2006	189
Table 4.41:	Forecast sales for Sanofi-Aventis' CNS portfolio, 2005–11	191
Table 4.42:	AstraZeneca's marketed CNS portfolio, 2005	192
Table 4.43:	AstraZeneca's CNS R&D pipeline, 2006	193
Table 4.44:	Forecast sales for AstraZeneca's CNS portfolio, 2005–11	194
Table 4.45:	Wyeth's marketed CNS portfolio, 2005	195
Table 4.46:	Wyeth's CNS R&D pipeline, 2006	196
Table 4.47:	Forecast sales for Wyeth's CNS portfolio, 2005–11	198
Table 4.48:	Novartis' marketed CNS portfolio, 2005	199
Table 4.49:	Novartis' CNS R&D pipeline, 2006	200
Table 4.50:	Forecast sales for Novartis' CNS portfolio, 2005–11	201
Table 4.51:	Forest's marketed CNS portfolio, 2005	202
Table 4.52:	Forest's CNS R&D pipeline, 2006	203
Table 4.53:	Forecast sales for Forest's CNS portfolio, 2005–11	205